Omega Therapeutics, Inc.
OMGA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $0 | $0 |
| % Growth | 49.3% | 1,339.6% | – | – |
| Cost of Goods Sold | $66 | $5 | $1 | $1 |
| Gross Profit | -$63 | -$3 | -$1 | -$1 |
| % Margin | -2,028.9% | -150.4% | -863.2% | – |
| R&D Expenses | $77 | $80 | $48 | $21 |
| G&A Expenses | $26 | $22 | $17 | $6 |
| SG&A Expenses | $26 | $22 | $17 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $2 | $1 |
| Operating Expenses | $103 | $105 | $66 | $29 |
| Operating Income | -$100 | -$103 | -$66 | -$29 |
| % Margin | -3,240.5% | -4,957.4% | -45,855.6% | – |
| Other Income/Exp. Net | $3 | $0 | -$2 | -$1 |
| Pre-Tax Income | -$97 | -$103 | -$68 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$97 | -$103 | -$69 | -$30 |
| % Margin | -3,148.9% | -4,951.1% | -48,029.2% | – |
| EPS | -1.8 | -2.14 | -1.45 | -0.63 |
| % Growth | 15.9% | -47.6% | -130.2% | – |
| EPS Diluted | -1.8 | -2.14 | -1.45 | -0.63 |
| Weighted Avg Shares Out | 54 | 48 | 48 | 48 |
| Weighted Avg Shares Out Dil | 54 | 48 | 48 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $1 | $1 |
| Depreciation & Amortization | $7 | $5 | $1 | $1 |
| EBITDA | -$93 | -$98 | -$65 | -$27 |
| % Margin | -3,021.7% | -4,707% | -44,892.4% | – |